Turning Point withdraws legal action after FDA back-tracks on PMTA refusal

The US Food and Drug Administration (FDA) has rescinded its marketing denial order (MDO) affecting 14 Turning Point Brands products, admitting that “relevant information that was not adequately assessed”. The company has responded by putting on hold a legal action against the agency.

In a letter to the vaping manufacturer and distributor, the FDA said the randomised trials and cross-sectional surveys that Turning Point Brands (TPB) presented in its premarket tobacco product applications (PMTAs) required “further review”.

Read full article
I'm already a subscriber
Author default picture


This article was written by one of ECigIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual vaping markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global e-cigarette market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

ECigIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization